Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 11/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28059267 | 0.79 | SYK (0.46) | PTK2ULK1GSK3AGSK3BJAK2 | |
| SCHEMBL25692091 | 0.79 | ULK1 (0.44) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL15937970 | 0.78 | MAPK3 (0.53) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL25234927 | 0.78 | PTK2 (0.49) | PTK2PTK2B | |
| SCHEMBL5563903 | 0.78 | CDC7 (0.55) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL12813038 | 0.77 | CDC7 (0.52) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL2029526 | 0.76 | PTK2 (0.58) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL15948509 | 0.75 | MAPK3 (0.53) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL19831480 | 0.75 | CDC7 (0.50) | PTK2MAPK3CDC7ROCK2MAP4K4 | |
| SCHEMBL1202633 | 0.75 | CDC7 (0.70) | CDC7ROCK2MAP4K4PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | PTK2 71/4885MAPK3 2/4885CDC7 181/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | PTK2 56/4885MAPK3 3/4885CDC7 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.